原发性肝癌患者临床诊疗现状分析及多学科协作诊疗的初步探讨

doi:10.3969/j.issn.1672-5069.2015.05.016

摘要/Abstract

摘要： 目的了解原发性肝癌（PLC）住院患者的临床基本特征及诊疗现况，探讨多学科协作诊疗模式（MDT）在原发性肝癌治疗中的应用价值。方法 2010年1月1日～2013年12月31日期间在南方医院诊疗的PLC患者5390例，对患者的性别、年龄、病因、HBeAg定性、HBV DNA定量、AFP定量、Child-Pugh分级、BCLC分期、治疗方式等临床资料进行回顾性分析。结果本组PLC患者以男性为主（87.4%），中位年龄为53岁，HBV感染率为84.15%，AFP阳性（≥20 μg/L）率为65.63%；HBeAg阳性患者AFP阳性率为76.95% （671/872），高于HBeAg阴性患者的54.11%（685/1266）或HBV DNA阳性（≥1.0×103 IU/ml）患者的70.73 （1022/1445，P<0.01）；患者年龄越小、肝功能越差、BCLC分期越晚，AFP阳性率越高（P<0.01）；PLC病理学分型以肝细胞癌（HCC）为主（84.7%）；BCLC分期以 C期（41.0%）和B期（31.0%）为主；仅10%PLC患者经过综合治疗；在1051例PLC患者中，初治即接受MDT诊疗的56例（5.3%），而28例（2.7%）非初治患者接受了MDT诊疗；在常规治疗情况下，单次平均住院费用为28234元，而MDT治疗的平均住院费用为26307元，费用减少了6.83%。结论 PLC患者多并有慢性HBV感染，且发病住院时多为中晚期，MDT诊疗模式可以减少住院费用。

关键词: 原发性肝癌, 巴塞罗那分期, 多学科协作诊疗模式, 甲胎蛋白

Abstract: Objective To investigate the clinical features of patients with primary liver cancer （PLC），and the current states of clinical diagnosis and multi-disciplinary team（MDT） management in clinical practice. Methods The clinical data of 5390 patients with PLC enrolled in our general hospital in south China from 1st Jan， 2010 to 30th Dec，2013 were retrieved，and we reviewed the patient's gender，age，etiology，qualitative detection of serum HBeAg，HBV DNA and alpha fetoprotein（AFP） levels，Child-Pugh class，Barcelona clinic liver cancer （BCLC） stages and the strategy of treatment for them. Results The median age of 5390 patients was 53-year-old，while male persons accounted for 87.4% and the prevalence of hepatitis B virus （HBV） infection was 84.15%；serum AFP positive（≥20 μg/L） accounted for 65.63%，and in HBeAg positive patients was 76.95% （671/872），much higher than that in HBeAg negative patients [54.11%（685/1266），P<0.01]；serum HBV DNA positive （≥1.0×103IU/ml） was 70.73 %（1022/1445）；as for pathological classification，the hepatocellular carcinoma （HCC） ranked first （84.7%）；the patients with BCLC stage C was 41.0% and B 31.0%；only 10% of PLC patients received comprehensive treatment；There were 56（5.3%） out of 1051 patients at initial admission，and 28 （2.7%） at repeated admission receiving MDT therapy；the hospitalization fee for conventional management was 28 thousand RMB，which was reduced by 6.83% to 26 thousand for MDT treatment. Conclusion The patients with PLC are often with underlying chronic HBV infection and are likely to be in advanced stage when hospitalized. The MDT should be recommended for their diagnosis and treatment.

Key words: Primary liver cancer, Barcelona clinic liver stage, Multi-disciplinary team, Fetoprotein

廖毓菁，黄静，胡晓云，郭亚兵. 原发性肝癌患者临床诊疗现状分析及多学科协作诊疗的初步探讨[J]. 实用肝脏病杂志, 2015, 18(5): 512-516.

Liao Yujing，Huang Jing，Hu Xiaoyun，et al.. A retrospective analysis of clinical diagnosis and multi-disciplinary team treatment in patients with primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 512-516.

参考文献

[1] Gish RG，Lencioni R，Di Bisceglie AM，et al． Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma． Expert Rev Gastroenterol Hepatol，2012，6（2）：173-185．
[2] 陈建国，陆建华，朱源荣，等．乙型肝炎病毒感染与肝癌发生的31年随访研究. 中华流行病学杂志，2010，31（7）：721-726．
[3] 陈建国，陈万青，张思维，等．中国2003-2007年肝癌发病率与死亡率分析．中华流行病学杂志，2012，33（6）：547-553．
[4] Ryder SD，British Society of Gastroenterology．Guidelines for the diagnosis and treatment of hepatocellular carcinoma in adults． Gut，2003，52：iii1-8．
[5] Kurpad R，Kim W，Rathmell WK，et al． A multidisciplinary approach to the management of urologic malignancies：does it influence diagnostic and treatment decisions． Urol Oncol，2011，29（4）：378-382．
[6] 王悦华，王珍．医学家整体治疗策略在肿瘤治疗设计中的作用．综述与进展，2011，40（7）：140-144．
[7] Chang TT，Liaw YF，Wu SS，et al． Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B． Hepatology，2010，52：886-893．
[8] Quiroz SC，Bucio L，Souza V，et al． Effect of endotoxin pretreatment on hepatic stellate cell response to ethanol and acetaldehyde． J Gastroenterol Hepatol，2001，16（11）：1267-1273．
[9] Evans AA，Chen G，Ross EA，et al． Eight-year follow-up of the 90，000-person HaiMen city cohort:I. Hepatocellular carcinoma mortality，risk factors，and gender differences． Canc Epidemiol Biomark Prev，2002，11：369-376．
[10] Alka S，Hemlata D，Vaishali C，et al．Hepatitis B viru surface（S） transactivator with DNA-binding properties． J Med Virol，2000，61：1-10．
[11] Murakami Y，Saigo K，Takashima H，et al． Large scaled analysis of HBV DNA integration in HBV related hepatocellular carcinomas． Gut，2005，54：1162-1168．
[12] Yang HI，Lu SN，Liaw YF，et al．Hepatitis B e antigen and the risk of the hepatocellular carcinoma．N Engl J Med，2002，347：168-174．
[13] Fattovich G，Stroffolini T，Zagin I，et al． Hepatocellular carcinoma in cirrhosis:incidence and risk factors． Gastroenterology，2004，127：S35-50．
[14] Cucchetti A，Trevisani F，Cescon M，et al． Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population． J Hepatol，2012，56（5）：1089-1096．
[15] Chen CJ，Yang HI，Su J，et al． Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level．JAMA，2006，295：65-73．
[16] Van Roey G，Fevery J，Van Steenbergen W，et al． Hepatocellular carcinoma in Belgiu: clinical and virological characteristics of 154 consecutive cirrhotic and non-cirrhotic patients． Eur J Gastroenterol Hepatol，2000，12：61-66．
[17] Wong GL，Chan HL，Mak CW，et al． Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis． Hepatology，2013，58（5）：1537-1547．
[18] Mok TS，Yu SC，Lee C，et al．Fasle-negative rate of abdominal sonography for detecting hepatocellular carcinoma in patients with hepatitis B and elevated serum fetoprotein levels．Am J Roentgenol，2004，183：453-458．
[19] ShirakawaH，Kumnuma T，Nishmiura Y，et al． Glypiean-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer．Int J Oncol，2009，34（3）：649-656．
[20] Baek YH，Lee JH，Jang JS，et al． Diagnostic role and correlation with staging system s of PIVKA-II compared with AFP．Hepatogastroenterology，2009，56（91-92）：763-767．
[21] Lok AS，Sterling RK，Everhart JE，et al． Des-gamma-carboxy prothromb in and alpha fetoprotein as biomarkers for the early detection of hepatocellular carcinoma． Gastroenterology，2010，138（2）：493-502．
[22] Lencioni R．Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies． Oncology，2010，78（suppl 1）：107-112．
[23] 骆抗先，陈金军，李平，等．乙型肝炎基础和临床．北京：人民卫生出版社，2007：647-650．
[24] Kim MY，Oskarsson T，Acharyya S，et al． Tumor self-seeding by circulating cancer cells． Cell，2009，139：1315-1326．
[25] Ferenci P，Fried M，Labrecque D，et al． World Gastroenterology Organisation Guideline. Hepatocellular carcinoma（HCC）:a global perspective． J Gastrointestin Liver Dis，2010，19（3）：311-317．
[26] Barone C，Koeberle D，Metselaar H，et al． Multidisciplinary approach for HCC patients:hepatology for the oncologists．Ann Oncol，2013，24（ suppl 2）：ii15-23．
[27] Patkar V，Acosta D，Davidson T，et al． Cancer multidisciplinary team meetings:evidence，challenges，and the role of clinical decision support technology． Int J Breast Cancer，2011：831605．
[28] Chang TT，Sawhney R，Monto A，et al． Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival．HPB（Oxford），2008，10（6）：405-411．
[29] 中国抗癌协会肝癌专业委员会，等．原发性肝癌规范化诊治的专家共识．实用肝脏病杂志，2009，12（5）：259-269．
[30] 广东省抗癌协会肝癌专业委员会，等．肝癌多学科联合治疗策略与方法—广东专家共识（2）．中国实用外科杂志，2014，8（34）：735-738．